Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Peptide PT-141 The recent FDA regulations have impacted the availability of certain substances essential for peptide production by compounding pharmacies
Critically, FOXO4-DRI does not predispose healthy cells to DNA damage or sensitize normal tissues to chemotherapy when administered prior to or during treatment
Ready to Use: Supplied as a liquid formulation, eliminating the need to reconstitute lyophilised peptide powder before research
Histological analysis showed that FOXO4-DRI treatment improved the testicular microenvironment, leading to thicker seminiferous epithelia, increased spermatogenic cells, and more mature spermatozoa in the central lumen
